Wegovy and Mounjaro to carry 'risk of blindness' warnings

‌In the United States, instructions for obesity treatments such as Wegovy and Mounjaro will soon include a new 'risk of vision impairment' warning. This follows a requirement from the U.S. Food and Drug Administration (FDA) to add warning labels, stating that there is a rare risk of optic nerve damage when using these drugs.
Reuters reported on the 9th that the FDA has instructed manufacturers to add warnings regarding the risk of vision impairment to the labels of GLP-1 class obesity and diabetes treatments, including Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Mounjaro and Zepbound.
The condition in question is 'Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION),' a type of 'optic nerve blood flow disorder.' It is a disease where vision suddenly drops because blood is not circulating properly to the optic nerve. It is characterized by a sudden loss of vision without pain. In severe cases, vision can be permanently damaged.
The FDA made this decision after reviewing clinical trials, animal studies, and data from patients who have used the actual drugs. Consequently, the instructions for GLP-1 class drugs will henceforth include information stating that the risk of developing this eye disease may increase.
Wegovy and Mounjaro to carry ‘risk of blindness’ warnings Chosun Biz In the United States, instructions for obesity treatments such as Wegovy and Mounjaro will soon include a new ‘risk of vision impairment’ warning. This follows a requirement from the U.S. Food and Drug Administration (FDA) to add warning labels, stating that there is a rare risk of optic nerve damage when using these drugs. The FDA has instructed Novo Nordisk's Wegovy, Ozempic, Eli Lilly's...
Wegovy and Mounjaro side effects include vision impairment, with the possibility of permanent vision loss.